Stock listing
OTC:AROAF Aroa Biosurgery Ltd Stock
US listing (OTC) of Aroa Biosurgery Ltd · home listing ASX:ARX
Follow Aroa Biosurgery Ltd into a list and get an email when it puts out news.
Home listing price · ASX:ARX
$0.485 AUD -0.020 (-4.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, ASX:ARX
- Day range
- $0.480 – $0.505 AUDNov 20, 2026
- Volume
- 192,342 sharesNov 20, 2026
- Market cap
- $170.1M AUDAt the close on Nov 20, 2026 · price × 350.7M shares outstanding
- 52-week range
- $0.465 – $0.775 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $112,115 AUDMedian day 131,185 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:ARX · Home | $0.485 AUD | -0.020 (-4.0%) | 192,342 | $0.495 | $0.505 | $0.480 | $0.505 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:ARX · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.485 | -0.020 | -4.0% | $0.495 | $0.505 | $0.480 | 192,342 | |
| $0.505 | +0.013 | +2.6% | $0.500 | $0.510 | $0.490 | 237,726 | |
| $0.492 | +0.012 | +2.5% | $0.490 | $0.500 | $0.480 | 313,072 | |
| $0.480 | -0.020 | -4.0% | $0.510 | $0.510 | $0.480 | 185,276 | |
| $0.500 | -0.010 | -2.0% | $0.505 | $0.510 | $0.500 | 846,693 | |
| $0.510 | +0.015 | +3.0% | $0.500 | $0.510 | $0.490 | 76,081 | |
| $0.495 | -0.015 | -2.9% | $0.510 | $0.510 | $0.490 | 74,287 | |
| $0.510 | +0.005 | +1.0% | $0.505 | $0.515 | $0.500 | 78,647 | |
| $0.505 | -0.025 | -4.7% | $0.530 | $0.530 | $0.495 | 149,591 | |
| $0.530 | +0.040 | +8.2% | $0.495 | $0.530 | $0.465 | 553,672 | |
| $0.490 | +0.005 | +1.0% | $0.515 | $0.515 | $0.490 | 64,693 | |
| $0.485 | -0.005 | -1.0% | $0.500 | $0.510 | $0.485 | 211,923 | |
| $0.490 | +0.005 | +1.0% | $0.500 | $0.520 | $0.485 | 248,655 | |
| $0.485 | -0.065 | -11.8% | $0.550 | $0.550 | $0.485 | 752,130 | |
| $0.550 | +0.015 | +2.8% | $0.535 | $0.550 | $0.515 | 203,047 | |
| $0.535 | +0.010 | +1.9% | $0.530 | $0.535 | $0.515 | 120,702 | |
| $0.525 | +0.005 | +1.0% | $0.520 | $0.525 | $0.515 | 57,326 | |
| $0.520 | -0.005 | -1.0% | $0.530 | $0.530 | $0.520 | 10,462 | |
| $0.525 | -0.015 | -2.8% | $0.535 | $0.540 | $0.515 | 89,312 | |
| $0.540 | +0.015 | +2.9% | $0.530 | $0.545 | $0.525 | 99,347 | |
| $0.525 | +0.015 | +2.9% | $0.510 | $0.530 | $0.510 | 123,081 | |
| $0.510 | 0.000 | 0.0% | $0.510 | $0.510 | $0.505 | 75,891 | |
| $0.510 | 0.000 | 0.0% | $0.505 | $0.510 | $0.505 | 93,948 | |
| $0.510 | 0.000 | 0.0% | $0.495 | $0.510 | $0.495 | 186,130 | |
| $0.510 | -0.030 | -5.6% | $0.550 | $0.550 | $0.510 | 197,026 | |
| $0.540 | +0.015 | +2.9% | $0.515 | $0.540 | $0.490 | 141,237 | |
| $0.525 | +0.025 | +5.0% | $0.500 | $0.525 | $0.500 | 92,107 | |
| $0.500 | -0.005 | -1.0% | $0.510 | $0.510 | $0.495 | 2,009,819 | |
| $0.505 | -0.015 | -2.9% | $0.530 | $0.530 | $0.500 | 122,781 | |
| $0.520 | 0.000 | 0.0% | $0.550 | $0.550 | $0.520 | 122,371 | |
| $0.520 | -0.015 | -2.8% | $0.535 | $0.535 | $0.515 | 243,140 | |
| $0.535 | +0.035 | +7.0% | $0.515 | $0.540 | $0.515 | 259,547 | |
| $0.500 | +0.005 | +1.0% | $0.510 | $0.510 | $0.500 | 460,913 | |
| $0.495 | +0.005 | +1.0% | $0.500 | $0.525 | $0.495 | 887,964 | |
| $0.490 | 0.000 | 0.0% | $0.500 | $0.500 | $0.475 | 193,991 | |
| $0.490 | -0.035 | -6.7% | $0.500 | $0.505 | $0.490 | 417,860 | |
| $0.525 | +0.035 | +7.1% | $0.500 | $0.525 | $0.480 | 590,468 | |
| $0.490 | -0.010 | -2.0% | $0.490 | $0.505 | $0.490 | 203,244 | |
| $0.500 | -0.010 | -2.0% | $0.505 | $0.510 | $0.495 | 135,951 | |
| $0.510 | -0.015 | -2.9% | $0.525 | $0.525 | $0.510 | 109,162 | |
| $0.525 | -0.005 | -0.9% | $0.540 | $0.545 | $0.525 | 5,128 | |
| $0.530 | +0.005 | +1.0% | $0.520 | $0.530 | $0.520 | 193,745 | |
| $0.525 | +0.005 | +1.0% | $0.540 | $0.545 | $0.515 | 126,419 | |
| $0.520 | -0.010 | -1.9% | $0.540 | $0.540 | $0.515 | 163,464 | |
| $0.530 | 0.000 | 0.0% | $0.540 | $0.550 | $0.530 | 40,686 | |
| $0.530 | -0.010 | -1.9% | $0.545 | $0.550 | $0.525 | 26,695 | |
| $0.540 | -0.020 | -3.6% | $0.555 | $0.555 | $0.540 | 17,385 | |
| $0.560 | +0.005 | +0.9% | $0.550 | $0.560 | $0.535 | 200,729 | |
| $0.555 | +0.005 | +0.9% | $0.550 | $0.555 | $0.535 | 423,133 | |
| $0.550 | +0.015 | +2.8% | $0.530 | $0.550 | $0.515 | 257,355 | |
| $0.535 | -0.010 | -1.8% | $0.540 | $0.550 | $0.535 | 24,698 | |
| $0.545 | +0.005 | +0.9% | $0.540 | $0.550 | $0.530 | 46,843 | |
| $0.540 | -0.020 | -3.6% | $0.560 | $0.560 | $0.540 | 55,435 | |
| $0.560 | +0.005 | +0.9% | $0.555 | $0.560 | $0.550 | 33,040 | |
| $0.555 | +0.015 | +2.8% | $0.550 | $0.560 | $0.540 | 83,651 | |
| $0.540 | 0.000 | 0.0% | $0.550 | $0.550 | $0.540 | 1,784 | |
| $0.540 | -0.010 | -1.8% | $0.545 | $0.550 | $0.540 | 113,354 | |
| $0.550 | -0.005 | -0.9% | $0.560 | $0.560 | $0.545 | 85,927 | |
| $0.555 | -0.010 | -1.8% | $0.560 | $0.560 | $0.550 | 71,026 | |
| $0.565 | +0.010 | +1.8% | $0.570 | $0.575 | $0.555 | 349,870 | |
| $0.555 | -0.005 | -0.9% | $0.580 | $0.580 | $0.555 | 121,789 | |
| $0.560 | -0.005 | -0.9% | $0.570 | $0.575 | $0.560 | 47,151 | |
| $0.565 | -0.010 | -1.7% | $0.575 | $0.575 | $0.555 | 178,273 | |
| $0.575 | +0.005 | +0.9% | $0.570 | $0.580 | $0.565 | 51,895 | |
| $0.570 | -0.010 | -1.7% | $0.580 | $0.580 | $0.570 | 175,560 | |
| $0.580 | 0.000 | 0.0% | $0.595 | $0.595 | $0.575 | 234,963 |
Splits
2 splits since 2016 · ASX:ARX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split | |
| 1-for-500 | Consolidation |
- Ticker
- OTC:AROAF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
US CMS Confirms Symphony Outpatient Reimbursement Rate
Latest deck · Oct 12, 2026
Investor Presentation (October 2026)
Investor deck · 26 slides
Latest news
US CMS Confirms Symphony Outpatient Reimbursement Rate
Nov 8, 2026
Closed $0.505 (-4.7%) on Nov 9, 2026
Aroa Biosurgery H1 FY27 Results & Investor Event
Nov 3, 2026
Closed $0.485 (-1.0%) on Nov 4, 2026
AROA Appoints Mark Dunwoodie as CFO
Nov 2, 2026
Closed $0.49 (+1.0%) on Nov 3, 2026
Change in substantial shareholding for ARX
Oct 18, 2026
Closed $0.51 (0.0%) on Oct 19, 2026
Molnlycke to Co-promote Endoform In the US
Oct 15, 2026
Closed $0.51 (-5.6%) on Oct 16, 2026
Notification of cessation of securities - ARX
Oct 12, 2026
Closed $0.50 (-1.0%) on Oct 13, 2026
Investor Presentation - Symphony RCT
Oct 11, 2026
Closed $0.505 (-2.9%) on Oct 12, 2026
Invite to Investor Webinar on Symphony RCT
Oct 6, 2026
Closed $0.535 (+7.0%) on Oct 7, 2026
Investor Presentation - MASTRR Interim Analysis
Oct 6, 2026
Closed $0.535 (+7.0%) on Oct 7, 2026
Change in substantial holding
Oct 6, 2026
Closed $0.50 (+1.0%) on Oct 6, 2026
Aroa Biosurgery Ltd on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 35 in the last 12 months · 81 in all · newest Nov 9, 2026 · oldest 2020
- Decks
- 39 decks · latest Oct 12, 2026
Where Aroa Biosurgery Ltd is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:ARX · Home listing | ASX | Australia | AUD |
| OTC:AROAF · This page | OTC | United States | USD |
Valuation
P/E 40.9× against a median of 8.5×: 5th lowest of 6 Medical devices & supplies companies shown. Statements: Year to Mar 31, 2026 · price Nov 20, 2026
- Enterprise value
- $152.8M AUD
- P/E
- 40.9×
- EV/sales
- 1.7×
- EV/EBITDA
- 16.9×
- Price/book
- 2.1×
- Gross margin
- 86.3%
- Operating margin
- 4.7%
- Net margin
- 4.5%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Aroa Biosurgery Ltd · ASX:ARX | US$112.6M | US$101.1M | 40.9× | 1.7× | 16.9× | 2.1× | 4.5% | 0.1× | n/a |
| Mercator Medical SA · GPW:MRC | US$123.9M | US$87.98M | 7.6× | 0.6× | 4.5× | 0.5× | 10.7% | 0.0× | n/a |
| Edap Tms SA · NASDAQ:FOCL | US$123.2M | US$103.0M | n/a | 1.3× | n/a | 3.4× | −47.0% | 1.0× | 1.17 |
| St.Shine Optical Co., Ltd. · TPEX:1565 | US$117.8M | US$48.97M | 8.5× | 0.4× | 2.0× | 0.6× | 11.1% | 0.0× | n/a |
| MediNice SA · GPW:ICE | US$114.5M | US$113.6M | n/a | n/a | n/a | 5.5× | n/a | 0.0× | n/a |
| Allgens Medical Technology Co. Ltd. Class A · SSE:688613 | US$112.4M | −US$36.15M | 94.7× | −1.1× | n/a | 0.5× | 3.5% | 0.0× | n/a |
| Pulmonx Corporation · NASDAQ:LUNG | US$111.9M | US$97.15M | n/a | 1.1× | n/a | 3.3× | −47.9% | 1.1× | 1.95 |
| Laxmi Dental Ltd. · NSE:LAXMIDENTL | US$111.4M | US$110.1M | 31.9× | 3.5× | 20.4× | 3.9× | 11.0% | 0.1× | n/a |
| Interojo Inc. · KRX:119610 | US$106.3M | US$84.65M | 8.0× | 0.9× | 3.4× | 0.9× | 14.3% | 0.0× | n/a |
| Onward Medical N.V. · EURONEXT:ONWD | US$106.1M | US$31.75M | n/a | 5.3× | n/a | 1.3× | −771.8% | 0.2× | n/a |
| Orthocell Ltd · ASX:OCC | US$102.8M | US$74.57M | n/a | 9.9× | n/a | 4.5× | −122.0% | 0.1× | n/a |
| Median of the others | US$112.2M | US$86.31M | 8.5× | 1.1× | 4.0× | 2.3× | 3.5% | 0.0× | 1.56 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.08 AUD · Analysts' mean
- EPS, year to Mar 2027
- 0.016 · 3 analysts
- Revenue, year to Mar 2027
- 120.6M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Brian Ward | Founder and Chief Executive Officer |
| Mark Dunwoodie | CFO |
| Rod Stanley | Chief Operating Officer |
| James Agnew | Joint Company Secretary |
| Barnaby C. H. May | Chief Scientific Officer |
| Michael Lynskey | |
| Yasmin Winchester | Chief of Technical Operations |
Board
| Director | Role |
|---|---|
| Jim McLean | Independent, Non-Executive Director and Chair |
| Brian Ward | Founder and Chief Executive Officer |
| Catherine Mohr | Non-Executive Director |
| Darla Hutton | Independent, Non-Executive Director |
| Paul Shearer | Independent, Non-Executive Director |
| Phil McCaw B.B.S. | Non-Executive Director |
Events
- Next results
- Nov 24, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Nov 24, 2025 | −5.2% |
| Q4 2025 | May 28, 2025 | +14.0% |
| Q2 2025 | Nov 25, 2024 | +2.3% |
| Q3 2022 | Mar 31, 2022 | +4.0% |
| Q1 2022 | Sep 12, 2021 | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 26 slides | Oct 12, 2026 |
| Technical Presentation (October 2026) | Technical | 23 slides | Oct 7, 2026 |
| Shareholder Meeting (August 2026) | Shareholder meeting | 11 slides | Aug 19, 2026 |
| FY2026 Earnings Presentation | Earnings | 31 slides | May 26, 2026 |
| FY2026 Earnings Presentation | Earnings | 30 slides | May 26, 2026 |
| Corporate Update (February 2026) | Corporate update | 10 slides | Feb 3, 2026 |
| H1 FY26 Earnings Presentation | Earnings | 70 slides | Nov 25, 2025 |
| Q2 FY26 Earnings Presentation | Earnings | 25 slides | Oct 16, 2025 |
| Shareholder Meeting (August 2025) | Shareholder meeting | 22 slides | Aug 20, 2025 |
| Q1 FY26 Earnings Presentation | Earnings | 24 slides | Jul 29, 2025 |
All 39 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2025 Earnings Presentation | Earnings | 32 slides | May 29, 2025 |
| Q4 FY2025 Earnings Presentation | Earnings | 10 slides | Apr 29, 2025 |
| Q2 FY25 Earnings Presentation | Earnings | 16 slides | Jan 29, 2025 |
| H1 FY25 Earnings Presentation | Earnings | 52 slides | Nov 26, 2024 |
| Q2 FY25 Earnings Presentation | Earnings | 13 slides | Oct 22, 2024 |
| Q1 FY25 Earnings Presentation | Earnings | 23 slides | Jul 24, 2024 |
| Shareholder Meeting (July 2024) | Shareholder meeting | 21 slides | Jul 23, 2024 |
| FY2024 Earnings Presentation | Earnings | 27 slides | May 21, 2024 |
| Q4 FY24 Earnings Presentation | Earnings | 10 slides | Apr 30, 2024 |
| Q3 FY24 Earnings Presentation | Earnings | 9 slides | Jan 30, 2024 |
| H1 FY24 Earnings Presentation | Earnings | 24 slides | Nov 28, 2023 |
| Bell Potter Healthcare Conference November 2023 | Conference | 14 slides | Nov 14, 2023 |
| Q2 FY24 Earnings Presentation | Earnings | 15 slides | Oct 31, 2023 |
| Shareholder Meeting (August 2023) | Shareholder meeting | 29 slides | Aug 3, 2023 |
| Investor Presentation (June 2023) | Investor deck | 72 slides | Jun 1, 2023 |
| FY2023 Earnings Presentation | Earnings | 20 slides | May 31, 2023 |
| Q4 FY23 Earnings Presentation | Earnings | 13 slides | Apr 27, 2023 |
| Corporate Update (January 2023) | Corporate update | 15 slides | Jan 31, 2023 |
| H1 FY23 Earnings Presentation | Earnings | 14 slides | Nov 29, 2022 |
| H1 FY23 Earnings Presentation | Earnings | 14 slides | Oct 25, 2022 |
| Shareholder Meeting (August 2022) | Shareholder meeting | 17 slides | Aug 10, 2022 |
| FY2022 Earnings Presentation | Earnings | 15 slides | May 24, 2022 |
| Investor Presentation (April 2022) | Investor deck | 29 slides | Apr 26, 2022 |
| Bell Potter Healthcare Conference 2021 | Conference | 12 slides | Nov 9, 2021 |
| Investor Presentation (July 2021) | Investor deck | 41 slides | Jul 29, 2021 |
| Shareholder Meeting (July 2021) | Shareholder meeting | 8 slides | Jul 20, 2021 |
| Investor Day (July 2021) | Investor day | 71 slides | Jul 5, 2021 |
| FY2021 Earnings Presentation | Earnings | 20 slides | May 25, 2021 |
| IPO Roadshow (July 2020) | IPO roadshow | 34 slides | Jul 30, 2020 |
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.3M | 77.0M | 63.4M | 59.3M | 36.9M | 20.5M | 24.3M | 21.8M | 9.66M | 0 |
| Cost of revenue | 12.7M | 11.0M | 9.26M | 9.25M | 8.72M | 6.26M | 6.33M | 8.04M | 5.45M | 54.0K |
| Gross profit | 79.6M | 66.0M | 54.1M | 50.1M | 28.2M | 14.3M | 17.5M | 13.7M | 4.21M | 0 |
| Research and development | 7.05M | 8.69M | 8.40M | 9.93M | 7.76M | 5.90M | 4.48M | 4.07M | 2.89M | |
| Selling, general and administrative | 63.6M | 60.9M | 597.6K | 47.7M | 28.5M | 20.0M | 16.7M | 11.9M | 3.90M | 786.7K |
| Operating income | 4.36M | -8.13M | -9.79M | -2.91M | -6.98M | -10.3M | -2.83M | -179.3K | -2.24M | -842.8K |
| Depreciation and amortization | 4.67M | 4.50M | 4.09M | 3.50M | 2.95M | 3.05M | 2.61M | 1.93M | 681.8K | 1.77K |
| EBITDA | 9.03M | -3.62M | -5.70M | 593.9K | -4.03M | -7.28M | -219.5K | 1.75M | -1.56M | -841.0K |
| Interest expense | 420.3K | 439.7K | 1.16M | 344.4K | 1.08M | 400.6K | 228.0K | 2.57M | 62.8K | 0 |
| Income before tax | 3.85M | -2.95M | -9.56M | -359.4K | -7.68M | -17.5M | -5.85M | -2.84M | -1.46M | -722.7K |
| Income tax | -310.1K | 511.6K | 184.4K | 11.2K | 116.2K | 98.2K | -191.9K | -3.74M | -284.5K | 0 |
| Net income | 4.16M | -3.47M | -9.75M | -370.7K | -7.79M | -17.6M | -5.66M | 896.3K | -1.18M | -722.7K |
| Earnings per share, basic | 0.01 | -0.01 | -0.03 | -0.00 | -0.02 | -0.06 | -0.02 | 0.00 | -0.00 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.5M | 7.26M | 10.6M | 8.93M | 5.73M | 32.5M | 41.5M | 4.28M | 3.65M | 800.1K |
| Short-term investments | 5.06M | 12.9M | 17.2M | 34.1M | 47.6M | 1.45M | 944.7K | 9.60K | 37.0K | 37.0K |
| Receivables | 33.8M | 14.8M | 24.1M | 13.4M | 16.0M | 6.60M | 7.16M | 5.25M | 2.48M | 8.53K |
| Inventory | 5.01M | 7.52M | 7.43M | 4.52M | 3.70M | 3.31M | 3.88M | 2.57M | 1.68M | |
| Current assets | 64.4M | 62.0M | 63.3M | 73.1M | 74.2M | 44.8M | 17.4M | 12.6M | 8.89M | 922.1K |
| Property, plant and equipment | 21.5M | 22.2M | 20.6M | 15.4M | 12.7M | 8.73M | 6.09M | 5.42M | 5.41M | |
| Goodwill | 4.61M | 5.03M | 5.08M | 5.18M | 5.15M | 5.08M | 5.36M | 5.32M | 5.32M | |
| Total assets | 100.5M | 98.9M | 101.9M | 109.1M | 104.7M | 73.1M | 44.5M | 38.0M | 14.3M | 6.52M |
| Accounts payable | 4.88M | 1.51M | 1.57M | 1.79M | 1.24M | 679.3K | 1.16M | 435.9K | 674.3K | 136.3K |
| Current liabilities | 13.5M | 9.36M | 8.73M | 7.41M | 6.24M | 14.0M | 6.13M | 7.83M | 2.25M | 175.3K |
| Long-term debt | 0 | 1.12M | 431.0K | 1.39M | ||||||
| Total debt | 5.31M | 5.83M | 6.82M | 7.07M | 5.83M | 15.4M | 10.8M | 1.09M | 1.52M | |
| Total liabilities | 17.7M | 14.3M | 14.8M | 13.7M | 11.3M | 19.4M | 19.7M | 26.4M | 12.5M | 234.7K |
| Shareholders' equity | 82.7M | 84.6M | 87.1M | 95.4M | 93.4M | 53.7M | 62.9M | 11.5M | 1.77M | 6.28M |
| Shares outstanding | 363.5M | 344.9M | 343.8M | 342.9M | 342.2M | 300.4M | 300.1M | 300.1M | 300.1M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 9.37M | -2.33M | -6.76M | -3.53M | -10.7M | -5.01M | 1.58M | -6.54K | -2.80M | -737.1K |
| Capital spending | -985.5K | -3.36M | -3.23M | -7.12M | -4.53M | -1.38M | -1.78M | -1.53M | -1.55M | -40.9K |
| Free cash flow | 8.39M | -5.69M | -10.00M | -10.7M | -15.4M | -1.38M | -199.5K | -1.54M | -4.36M | -777.9K |
| Cash from investing | 3.80M | 273.5K | 9.31M | 6.79M | -32.4M | -21.5M | -1.78M | -3.46M | 4.91M | 339 |
| Cash from financing | -1.55M | -1.34M | -948.4K | -471.8K | 35.0M | 34.1M | -364.9K | 3.86M | 410.2K | 858.9K |
| Dividends paid | -0 | -18.2M | ||||||||
| Share buybacks | -1.35M | -1.13M | -958.5K | -2.06M | -3.97M | 296.0K | 8.87M | 48.0K | 917.5K | |
| Change in cash | 10.3M | -3.21M | 1.82M | 3.16M | -8.57M | 10.6M | -549.9K | 631.9K | 2.52M | 120.4K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| US CMS Confirms Symphony Outpatient Reimbursement Rate | Nov 8, 2026 | Guidance | ASX |
| Aroa Biosurgery H1 FY27 Results & Investor Event | Nov 3, 2026 | Results | ASX |
| AROA Appoints Mark Dunwoodie as CFO | Nov 2, 2026 | Management or board change | ASX |
| Change in substantial shareholding for ARX | Oct 18, 2026 | Other filings | ASX |
| Molnlycke to Co-promote Endoform In the US | Oct 15, 2026 | Other filings | ASX |
| Notification of cessation of securities - ARX | Oct 12, 2026 | Financing | ASX |
| Investor Presentation - Symphony RCT | Oct 11, 2026 | Other filings | ASX |
| Invite to Investor Webinar on Symphony RCT | Oct 6, 2026 | Other filings | ASX |
| Investor Presentation - MASTRR Interim Analysis | Oct 6, 2026 | Operations update | ASX |
| Change in substantial holding | Oct 6, 2026 | Ownership change notice | ASX |
All 74 filings
Cap table
Built by 6ix from Aroa Biosurgery Ltd’s releases
- Common shares
- 350,662,504
- Fully diluted
- 350,662,504
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 350,662,504 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 350,662,504 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Barnaby C. H. May | Chief Scientific Officer · Since at least May 2, 2025 |
| Brian Ward | Founder and Chief Executive Officer · Since at least Nov 3, 2026 |
| Catherine Mohr | Non-Executive Director · Since at least Nov 5, 2026 |
| Darla Hutton | Independent, Non-Executive Director · Since at least Nov 5, 2026 |
| James Agnew | Joint Company Secretary · Since at least Nov 4, 2026 |
| Jim McLean | Independent, Non-Executive Director and Chair · Since at least Nov 5, 2026 |
| Mark Dunwoodie | CFO · Since at least Nov 2, 2026 |
| Michael Lynskey | Officer · Since at least Jul 27, 2026 |
| Paul Shearer | Independent, Non-Executive Director · Since at least Nov 5, 2026 |
| Phil McCaw B.B.S. | Non-Executive Director · Since at least Nov 5, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Rod Stanley | Chief Operating Officer · Since at least Nov 4, 2026 |
| Yasmin Winchester | Chief of Technical Operations · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Aroa Biosurgery Ltd.